Bearish Stocks at NASDAQ: Conatus Pharmaceuticals (NASDAQ:CNAT), Metabolix (NASDAQ:MBLX), Clovis Oncology (NASDAQ:CLVS), Oculus Innovative Sciences (NASDAQ:OCLS)

On March 27, 2014, Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) issued a press release announcing its financial results for the quarter and year ended December 31, 2013. Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) stock performance was -15.63% in last session and finished the day at $8.42. Traded volume was 1.28 million shares in the last session and the average volume of the stock remained 473,716.00 shares. Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) insider ownership is 0.30%.

On March 27, 2014, Metabolix, Inc. (NASDAQ:MBLX) issued a press release announcing the financial results for its year ended December 31, 2013. Metabolix, Inc. (NASDAQ:MBLX) dropped -14.29% to $1.20 Friday on volume of 405,500.00 shares. The intra-day range of the stock was $1.10 – $1.28. Metabolix, Inc. (NASDAQ:MBLX) has a market capitalization of 41.50 million.

Boulder-based Clovis Oncology Inc. (NASDAQ:CLVS) (NASDAQ:CLVS) reported Thursday from a conference in Geneva, Switzerland, that it’s orally delivered drug, CO-1686, is providing benefits to patients suffering from lung cancer and is being well-tolerated as doses are increased. Clovis Oncology Inc. (NASDAQ:CLVS)’s stock on March 28, 2014 reported a lower of -12.44% to the closing price of $70.33. Its fifty two weeks range is $27.17 – $93.33. The total market capitalization recorded 2.38 billion. The overall volume in the last trading session was 1.89 million shares. In its share capital, Clovis Oncology Inc. (NASDAQ:CLVS) has 33.90 million outstanding shares.

Oculus Innovative Sciences, Inc. (NASDAQ:OCLS), on March 27 announced the appointment of Sharon Barbari to its board of directors, effective March 26, 2014. On Friday, shares of Oculus Innovative Sciences, Inc. (NASDAQ:OCLS) dropped -11.49% to close the day at $3.85. Company return on investment (ROI) is -54.10% and its monthly performance is recorded as -1.03%. Oculus Innovative Sciences, Inc. (NASDAQ:OCLS) quarterly revenue growth is 6.06%.

Signup for free to be the first to receive exclusive free links. Now in your mailbox!
Join over 15,000 subscribers
Send me links

Your information will not be shared to anyone